All posts by: Michael Zand

About Michael Zand

Stem cells offer hope for autism – CBS46 News – CBS46 News Atlanta

Continue reading

2017-04-06 NEWS

CBS46 News Atlanta

Stem cells offer hope for autism – CBS46 News
CBS46 News Atlanta
Gracie Gregory smiles beneath her brilliant blue eyes. She’s sitting on her mother’s lap, next to her older sister, Ryleigh, who boasts about Gracie being “very …
Health Highlights: April 6, 2017U.S. News & World Report

all 2 news articles »

Continue reading

2017-04-06 NEWS

KMOV.com

Stem cells offer hope for autism – KMOV.com
KMOV.com
Gracie Gregory smiles beneath her brilliant blue eyes. She’s sitting on her mother’s lap, next to her older sister, Ryleigh, who boasts about Gracie being “very …

and more »

Continue reading

2017-04-06 NEWS

Biodesix Adding Immunotherapy Test to Lung Cancer Portfolio
GenomeWeb
NEW YORK (GenomeWeb) – Molecular diagnostics firm Biodesix plans this year to launch a proteomic test for guiding immunotherapy in non-small cell lung cancer patients as it continues to build out its lung cancer offerings. The company aims to release

Continue reading

2017-04-06 NEWS

R & D Magazine

Featured R&D 100 Award Winner: Sanger Arrayed Lentiviral CRISPR Libraries
R & D Magazine
Sanger Arrayed Lentiviral CRISPR Library is a whole human genome “arrayed” library in glycerol format, meaning 1 gRNA in each well of 383 x 96-well plates. The arrayed library is a tool to allow for the systematic targeted knockout of 17,167 individual …

Continue reading

2017-04-06 NEWS

FierceBiotech

Spark hemophilia B gene therapy clears another early test
FierceBiotech
Spark Therapeutics has posted fresh data from a phase 1/2 trial of its hemophilia B gene therapy, SPK-9001. The data suggest Spark’s tapering courses of steroids successfully arrested the factor IX (FIX) declines seen in two patients who appeared to
Spark carefully records a safe step forward for closely-watched hemophilia gene therapyEndpoints News
Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and …GlobeNewswire (press release)

all 3 news articles »